Inhibrx Biosciences Inc. (INBX) Financials
INBX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 154.2 million | 207.2 million |
| March 31, 2026 | 184.0 million | 205.0 million |
| Dec. 31, 2025 | 146.5 million | 138.5 million |
| Sept. 30, 2025 | 177.5 million | 140.6 million |
INBX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -29.9 million | 3.1 million |
| March 31, 2026 | -38.0 million | 2.7 million |
| Dec. 31, 2025 | -30.1 million | 2.7 million |
| Sept. 30, 2025 | -33.8 million | 3.2 million |
INBX Net Income
Graph available only for paid members. Upgrade to see it.
| Date | Net Income |
|---|---|
| June 30, 2026 | -36.7 million |
| March 31, 2026 | -33.4 million |
| Dec. 31, 2025 | -32.8 million |
| Sept. 30, 2025 | -35.3 million |
INBX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 133.3 million | 2.9 million | - |
| March 31, 2026 | 161.7 million | 3.5 million | 5.9 million |
| Dec. 31, 2025 | 124.2 million | 100.6 million | 4.1 million |
| Sept. 30, 2025 | 153.1 million | 4.7 million | 7.0 million |
INBX Shares Outstanding
INBX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 27000 | 23.9 million | 8.3 million | - |
| March 31, 2026 | - | 24.7 million | 5.7 million | -7000 |
| Dec. 31, 2025 | - | 25.3 million | 5.6 million | - |
| Sept. 30, 2025 | 10000 | 28.5 million | 5.3 million | - |
INBX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | 537000 |
| Dec. 31, 2025 | - | 564000 |
| Sept. 30, 2025 | - | 582000 |
INBX Revenue by Segment
Graph available only for paid members. Upgrade to see it.
INBX
Price: $88.37
52 week price:
Earnings Per Share: -8.12 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 275430
Market Capitalization: 1.3 billion